Efektivitas Vaksinasi terhadap Tingkat Keparahan Covid-19
Abstract
Keywords
Full Text:
PDFReferences
kemkes RI. Antisipasi Gelombang Ketiga, Kenali Ciri dan Cara Mencegah Penularan Omicron. https://www.kemkes.go.id/article/view/22012700001/antisipasi-gelombang-ketiga-kenali-ciri-dan-cara-mencegah-penularan-omicron.html (2022).
RI, K. Kasus Pertama Omicron di Indonesia. Kasus Omicron Pertama di Indonesia https://sehatnegeriku.kemkes.go.id/baca/rilis-media/20211219/5339013/kasus-pertama-omicron-di-indonesia-diduga-dari-wni-yang-datang-dari-nigeria/.
Burhan, E. et al. Pedoman Tatalaksana COVID-19 Edisi 4 Januari 2022. Pedoman tatalaksana COVID-19 edisi 4 (2022).
RI, D. J. P. K. K. Dukungan RSJPDHK dalam Pelaksanaan Vaksinasi Di Istana Negara. https://yankes.kemkes.go.id/read/207/dukungan-rsjpdhk-dalam-pelaksanaan-vaksinasi-di-istana-negara.
Kemkes RI. Vaksinasi COVID-19 untuk Anak Usia 6-11 Tahun dimulai 14 Desember. https://www.kemkes.go.id/article/view/21121300001/vaksinasi-covid-19-untuk-anak-usia-6-11-tahun-dimulai-14-desember.html.
COVID-19.go.id. Vaksin COVID-19 Moderna Diprioritaskan Jadi Dosis Ketiga (Booster) untuk Tenaga Kesehatan. https://covid19.go.id/edukasi/masyarakat-umum/vaksin-covid-19-moderna-diprioritaskan-jadi-dosis-ketiga-booster-untuk-tenaga-kesehatan.
COVID-19.go.id. Situasi COVID-19 di Indonesia Update 17 Februari 2022. https://covid19.go.id/artikel/2022/02/17/situasi-covid-19-di-indonesia-update-17-februari-2022.
Pikobar. Kasus konfirmasi Jawa Barat per 17 Februari 2022. https://pikobar.jabarprov.go.id/distribution-case.
www.covid-19.go.id. Peta Sebaran COVID-19. https://covid19.go.id/peta-sebaran# (2022).
CDC. COVID-19 Vaccine Breakthrough Infections Reported to CDC —. MMWR. Morb. Mortal. Wkly. Rep. 70, 792–793 (2021).
Erawan, M. A. S. P., Zaid, Z., Pratondo, K. & Lestari, A. Y. Predicting Covid-19 Vaccination Intention: The Role of Health Belief Model of Muslim Societies in Yogyakarta. Al-Sihah Public Heal. Sci. J. 13, 36 (2021).
Kemkes RI. Jumlah Pasien COVID-19 di Rumah Sakit Rendah Walau Konfirmasi Kasus Harian Tinggi. https://www.kemkes.go.id/article/view/22020500001/jumlah-pasien-covid-19-di-rumah-sakit-rendah-walau-konfirmasi-kasus-harian-tinggi.html (2022).
Kemkominfo. 4 Upaya untuk Wujudkan Target Indonesia Dari Pandemi Menuju Endemi. https://covid19.go.id/edukasi/masyarakat-umum/4-upaya-untuk-wujudkan-target-indonesia-dari-pandemi-menuju-endemi (2021).
www.covid19.who.int. Dashboard COVID-19 in Malaysia. https://covid19.who.int/region/wpro/country/my (2022).
www.covid19.who.int. Dashboard COVID-19 in Vietnam. https://covid19.who.int/region/wpro/country/vn (2022).
www.covid19.who.int. Dashboard COVID-19 in Thailand. https://covid19.who.int/region/searo/country/th (2022).
Kumar, S., Thambiraja, T. S., Karuppanan, K. & Subramaniam, G. Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein. J. Med. Virol. 94, 1641–1649 (2022).
Saxena, S. K. et al. Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective. J. Med. Virol. 94, 1738–1744 (2022).
Kong, H. & Services, H. COVID-19. 2–7 (2021).
Poudel, S. et al. Highly mutated omicron variant sparks significant concern among global experts – What is known so far? Travel Med. Infect. Dis. 45, (2022).
Kim, H., Webster, R. G. & Webby, R. J. Influenza Virus: Dealing with a Drifting and Shifting Pathogen. Viral Immunol. 31, 174–183 (2018).
Juthani, P. V. et al. Hospitalisation among vaccine breakthrough COVID-19 infections. Lancet Infect. Dis. 21, 1485–1486 (2021).
Pollett, S. D. et al. The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccine-Breakthrough Infection Phenotype Includes Significant Symptoms, Live Virus Shedding, and Viral Genetic Diversity. Clin. Infect. Dis. 74, 897–900 (2022).
Dagan, N. et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N. Engl. J. Med. 384, 1412–1423 (2021).
Bhandari, S. et al. Patient Flow Dynamics in Hospital Systems During Times of COVID-19: Cox Proportional Hazard Regression Analysis. Front. Public Heal. 8, 1–7 (2020).
Bernal, J. L. et al. Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England. medRxiv 2021.03.01.21252652 (2021).
Bergwerk, M. et al. Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. N. Engl. J. Med. 385, 1474–1484 (2021).
Baden, L. R. et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 384, 403–416 (2021).
Polack, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).
Vasileiou, E. et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet 397, 1646–1657 (2021).
Novita Putri Evayanti, S. W. U. TINGKAT KEPARAHAN INFEKSI TEROBOSAN SARS-COV-2 SETELAH VAKSINASI COVID-19: TINJAUAN LITERATUR. J. Med. Hutama 3, 58–66 (2022).
DOI: http://dx.doi.org/10.7454/epidkes.v7i1.6374
Refbacks
- There are currently no refbacks.